Biologics Market by Source, Product, Indication, End-user

List of Tables

The Biologics Market was valued at USD 405.76 billion in 2023, expected to reach USD 430.59 billion in 2024, and is projected to grow at a CAGR of 6.39%, to USD 626.34 billion by 2030.

Biologics, a rapidly expanding segment within the pharmaceutical industry, encompass a diverse range of products derived from living organisms, such as vaccines, blood components, gene therapy, and monoclonal antibodies. The increasing prevalence of chronic diseases, advancements in biotechnology, and the need for targeted therapies underscore the necessity of biologics. Their applications span across treating diseases like cancer, rheumatoid arthritis, and multiple sclerosis, serving hospitals, research institutions, and specialty clinics. Key growth influencers include ongoing innovations in genetic engineering and cell therapy, alongside robust regulatory support facilitating expedited drug approvals. Additionally, partnerships between pharmaceutical companies and biotech startups are yielding breakthroughs, particularly in precision medicine and biosimilars-a class of drugs offering more affordable therapeutic alternatives. Opportunities lie in developing personalized treatment approaches and enhancing production scalability to meet growing demand. However, the biologics market faces limitations such as high R&D costs, complex manufacturing processes, and stringent regulatory requirements which often prolong time-to-market transitions. A key challenge is maintaining product stability and consistency. For market players, innovative areas include optimizing bioprocessing techniques and harnessing artificial intelligence to streamline drug discovery and development. Robust infrastructure for storage and distribution is also vital to overcoming cold chain limitations. The market is dynamic, characterized by high barriers to entry but also high rewards for successful innovation. To thrive, businesses should focus on strategic alliances for technology sharing, enhancing R&D efficiencies, and exploring emerging markets with unmet medical needs. Navigating the biologics landscape requires balancing cutting-edge scientific discovery with pragmatic supply chain management-a challenge that, if met, promises significant growth potential in improving global health outcomes.

KEY MARKET STATISTICS
Base Year [2023]	USD 405.76 billion
Estimated Year [2024]	USD 430.59 billion
Forecast Year [2030]	USD 626.34 billion
CAGR (%)	6.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Market

The Biologics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Rising prevalence of chronic diseases worldwide
- Growing need and preference for minimally invasive procedures
Market Restraints
- High cost of treatment associated with biologics
Market Opportunities
- Ongoing advancements in biomaterials improving the treatment of chronic disorders
- Rising expansion of manufacturing facilities associated with biologics
Market Challenges
- Availability of complex manufacturing of biologics

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Market

A detailed market share analysis in the Biologics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Market

A strategic analysis of the Biologics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Becton, Dickinson and Company, Biogen Inc., BioPharm Laboratories, LLC, Bristol Myers Squibb Company, Catalent, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Innovent Biologics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Biologics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Source, market is studied across Mammalian and Microbial.
Based on Product, market is studied across Antisense & RNAi Therapeutics, Monoclonal Antibodies, Recombinant Hormones or Proteins, and Vaccines.
Based on Indication, market is studied across Cardiovascular Disorders, Hematological Disorders, Immunological Disorders, Infectious Diseases, and Oncology.
Based on End-user, market is studied across Ambulatory Surgical Centers and Hospitals.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-4302AC72200D

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of chronic diseases worldwide
  - 5.1.1.2. Growing need and preference for minimally invasive procedures
- 5.1.2. Restraints
  - 5.1.2.1. High cost of treatment associated with biologics
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing advancements in biomaterials improving the treatment of chronic disorders
  - 5.1.3.2. Rising expansion of manufacturing facilities associated with biologics
- 5.1.4. Challenges
  - 5.1.4.1. Availability of complex manufacturing of biologics
5.2. Market Segmentation Analysis
- 5.2.1. Source: Mammalian cells are preferable for producing larger and more complex proteins
- 5.2.2. Indication: Ongoing innovations in oncology and infectious diseases driven by the COVID-19 pandemic and cancer research's evolution
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Biologics Market, by Source

6.1. Introduction
6.2. Mammalian
6.3. Microbial

7. Biologics Market, by Product

7.1. Introduction
7.2. Antisense & RNAi Therapeutics
7.3. Monoclonal Antibodies
7.4. Recombinant Hormones or Proteins
7.5. Vaccines

8. Biologics Market, by Indication

8.1. Introduction
8.2. Cardiovascular Disorders
8.3. Hematological Disorders
8.4. Immunological Disorders
8.5. Infectious Diseases
8.6. Oncology

9. Biologics Market, by End-user

9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Hospitals

10. Americas Biologics Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Biologics Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Biologics Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. FDA Approves First Tocilizumab Biosimilar, TOFIDENCE, Enhancing Access to Treatment for Autoimmune Diseases
- 13.3.2. Eli Lilly Expands Investment in Irish Biologics Manufacturing Facility
- 13.3.3. Sandoz Announces Major Investment in New Biologics Facility in Slovenia
13.4. Strategy Analysis & Recommendation

Companies Mentioned

1. AbbVie Inc.
2. Amgen Inc.
3. AstraZeneca PLC
4. Bayer AG
5. Becton, Dickinson and Company
6. Biogen Inc.
7. BioPharm Laboratories, LLC
8. Bristol Myers Squibb Company
9. Catalent, Inc.
10. F. Hoffmann-La Roche Ltd.
11. Genentech, Inc.
12. Gilead Sciences, Inc.
13. GlaxoSmithKline PLC
14. Innovent Biologics, Inc.
15. Johnson & Johnson Services, Inc.
16. Merck KGaA
17. Novartis AG
18. Pfizer Inc.
19. Sanofi S.A.
20. Thermo Fisher Scientific Inc.
21. Vertex Pharmaceuticals Inc.